•  
  •  
 

Article Type

Original Study

Abstract

The aim of this study was to perform systematic review to summarize the association of TRAIL receptor 1 polymorphism at codon A683C and C626G with cancer risk. Medline, articles in Medscape, AAFP, and PubMed were searched. The search was performed on 1 August 2016, and included all articles with no language restrictions. The initial search presented 219 articles. A total of 16 research studies met the inclusion criteria for the two DR4 polymorphisms; the articles included TRAIL receptor 1 polymorphism and increased cancer risk. Data from each eligible study were independently abstracted in duplicate using a data collection form to capture information on study characteristics, interventions, and quantitative results reported for each outcome of interest. There was heterogeneity in the collected data. It was not possible to perform meta-analysis. Significant data were collected. Thus, a structured review was performed. TRAIL receptor 1 polymorphism at codon A683C and C626G increases the risk of different types of malignancy such as hepatocellular carcinoma (HCC), gall bladder cancer, ovarian cancer, hematological system cancer, and bladder cancer, but without significant increase in the risk of other malignancies such as lung and breast cancers. A total of 14 articles were reviewed summarize the TRAIL receptor 1 polymorphism and cancer risk. Genotyping of this polymorphism at codon A683C and C626G can be used to assess patients' risk of developing cancer, which would allow early diagnosis with subsequent improvement in patient survival. Furthermore, TRAIL- directed therapy is likely to be beneficial in these cases.

Download

Share

COinS